Home » Stocks » Corcept Therapeutics

Corcept Therapeutics Incorporated (CORT)

Stock Price: $17.44 USD -0.34 (-1.91%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 2.02B
Revenue (ttm) 351.21M
Net Income (ttm) 114.11M
Shares Out 115.56M
EPS (ttm) 0.94
PE Ratio 18.55
Forward PE 17.48
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $17.44
Previous Close $17.78
Change ($) -0.34
Change (%) -1.91%
Day's Open 17.89
Day's Range 17.35 - 17.93
Day's Volume 485,707
52-Week Range 9.70 - 23.48

More Stats

Market Cap 2.02B
Enterprise Value 1.61B
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 115.56M
Float 104.20M
EPS (basic) 0.99
EPS (diluted) 0.94
FCF / Share 1.50
Dividend n/a
Dividend Yield n/a
Earnings Yield 5.39%
FCF Yield 8.58%
Payout Ratio n/a
Shares Short 19.04M
Short Ratio 2.88
Short % of Float 18.27%
Beta 0.70
PE Ratio 18.55
Forward PE 17.48
P/FCF Ratio 11.66
PS Ratio 5.74
PB Ratio 4.58
Revenue 351.21M
Operating Income 140.99M
Net Income 114.11M
Free Cash Flow 172.83M
Net Cash 401.85M
Net Cash / Share 3.48
Gross Margin 85.70%
Operating Margin 40.14%
Profit Margin 32.50%
FCF Margin 49.21%
ROA 21.32%
ROE 30.36%
ROIC 41.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 2
Overweight 0
Hold 1
Underweight 1
Sell 0

Analyst Consensus: Overweight

Price Target

$17.75*
(1.78% upside)
Low
7.00
Current: $17.44
High
26.00
Target: 17.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue30625115981.3250.2926.5510.363.31--
Revenue Growth21.99%57.82%95.77%61.72%89.39%156.36%213.18%---
Gross Profit30124615679.2648.9325.6710.213.22--
Operating Income11289.5052.8610.18-3.44-27.62-41.50-36.27-32.33-27.44
Net Income94.1875.411298.14-6.41-31.38-46.01-38.05-32.35-25.97
Shares Outstanding11411511411110710199.8293.0283.3168.34
Earnings Per Share0.770.601.040.07-0.06-0.31-0.46-0.41-0.39-0.38
EPS Growth28.33%-42.31%1385.71%-------
Operating Cash Flow13611660.9418.393.13-27.38-37.06-36.02-27.40-22.29
Capital Expenditures-1.09-0.30-0.42-0.19-0.02-0.17-0.13-0.15-0.03-
Free Cash Flow13511560.5218.203.11-27.55-37.19-36.17-27.43-22.29
Cash & Equivalents27620788.7451.5440.4424.2554.8893.0339.6424.58
Total Debt3.46--14.6627.4933.8935.0731.68--
Net Cash / Debt27320788.7436.8712.94-9.6419.8161.3539.6424.58
Assets41231222168.7551.9034.6363.0899.1739.8325.10
Liabilities41.1335.8129.5727.3733.4038.0242.0637.395.033.86
Book Value37127619141.3818.50-3.3921.0261.7834.8121.24
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Corcept Therapeutics Incorporated
Country United States
Employees 206
CEO Joseph K. Belanoff

Stock Information

Ticker Symbol CORT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CORT

Description

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushing's syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase I/II clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator that is in Phase II for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.